INTRODUCTION
Platelets form an integral part of the physiological response to vascular injury, where together with the products of the clotting cascade, they form a haemostatic plug that serves to stem the flow of blood from the injured vessel. Under normal conditions there is a fine balance between platelet activation and inhibition and any abnormal perturbation of this balance can result in serious disease states such as unstable angina, stroke and heart attack, or bleeding disorders. ADP is an important platelet activator and has been shown to be critical for a full platelet response at sites of vascular injury [1] [2] [3] [4] [5] . ADP activates platelets through two purinergic G-protein coupled receptors (GPCRs): P2Y 1 and P2Y 12 . P2Y 1 couples to Gαq and subsequent activation of phospholipase C and increase in cytosolic calcium 2, [6] [7] [8] . P2Y 1 has also been shown to couple to activation of p160 Rho kinase, and this, together with the increase in cytosolic calcium, is responsible for platelet shape change in response to ADP 7, [9] [10] [11] [12] [13] [14] . It is accepted, on the basis of P2Y 1 knockout studies and pharmacological blockade, that this receptor is absolutely required for both the ADP-induced rise in intracellular calcium and shape change responses, as selective inhibition of P2Y 1 results in abolition of these responses 2, 7, 8 .
The molecular identity of P2Y 12 remained elusive until recently 5 and was originally termed P2Y AC , P2T or P2 CYC . Pharmacological studies demonstrated that P2Y 1 alone was unable to account for all of the effects of ADP on platelet activation 2, 9, 15 and these additional activities were attributed to the P2Y 12 receptor, later shown to be coupled to inhibition of adenylate cyclase through Gαi 5, 9 . P2Y 12 was shown to play an important role in the reversible aggregation response to ADP, as well as potentiating aggregation responses to other agonists [16] [17] [18] [19] . More recently it has been questioned whether P2Y 12 -mediated inhibition of adenylate cyclase can account for all of the observed events downstream of P2Y 12 20-22 , and it has been
For personal use only. on . by guest www.bloodjournal.org From Reciprocal regulation of P2Y 1 and P2Y 12 signaling 4 subsequently demonstrated that P2Y 12 can also couple to activation of PI3-kinase (PI3K) 19, [23] [24] [25] . This has been shown to be important in mediating the pro-aggregatory properties of P2Y 12 , although the precise functional roles of PI3K remain to be elucidated 23, 24 . One possible role may involve modulation of the P2Y 1 -dependent calcium response by P2Y 12 .
Although pharmacological blockade or genetic removal of P2Y 1 27 have shown that P2Y 12 may be involved in the contribution to a cytosolic calcium rise by ADP, whereas Daniel et al.
(1998) 22 provide evidence that P2Y 12 is not involved in this process.
Two emerging themes in G protein-coupled receptor (GPCR) signalling and regulation are (i)
that GPCRs from different classes may regulate each other's activities through cross-talk mechanisms and (ii) that GPCRs can couple to signalling pathways distinct from the activation of G-proteins, specifically those involving tyrosine kinases. Here we address the question of interplay between these important ADP receptors, P2Y 1 and P2Y 12 , in human platelets using a variety of pharmacological approaches. We were able to show directly that P2Y 12 modulates the P2Y 1 -mediated calcium response through two of its signalling pathways; activation of PI3 kinase and inhibition of adenylate cyclase. In turn, we show that P2Y 1 feeds back negatively upon the PI3 kinase component of this response, and that this feedback is mediated through a novel activation of Src kinase. We hypothesise that this reciprocal receptor regulation may provide a means by which the delicate balance between resting and activated platelet states is maintained. 
METHODS

Materials
Monoclonal anti-Src antibody was from Upstate Biotechnology Ltd (Milton Keynes, UK).
Polyclonal rabbit anti-Src antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-specific antibodies anti-Src (Tyr416) and anti-PKB (Thr308) were from Cell Signaling Technologies (New England Biolabs, UK). Src family kinase inhibitor PP1 was from Alexis Corp (Nottingham, UK). The broad-spectrum phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), inactive PP1 analogue PP3 and Raytide peptide were from Calbiochem (La Jolla, CA, USA). Fura 2-AM, A3P5P, apyrase, forskolin, SQ22536 and BAPTA-AM were from Sigma (Poole, Dorset, U.K.). The P2Y 12 antagonist AR-C69931MX was a generous gift from AstraZeneca. 2-methylthio-AMP (2MeSAMP) was a kind gift from Dr Pamela Conley (Portola Pharmaceuticals Inc., CA, USA). γ-[ 
Preparation and stimulation of human platelets
Human blood was drawn from healthy, drug-free volunteers on the day of the experiment, under ethical approval from the Local Research Ethics Committee, United Bristol Healthcare Trust. Acid citrate dextrose (ACD: 120 mM sodium citrate, 110 mM glucose, 80 mM citric acid, used at 1:7 vol/vol) was used as anticoagulant. Platelet rich plasma (PRP) was prepared by centrifugation at 200g, for 17 min and platelets were then isolated by centrifugation for 10 min at 400g, in the presence of 0.02 u/ml apyrase and prostaglandin E 1 (PGE 1 ; 140 nM) for all assays other than measurement of intracellular cyclic AMP (cAMP), or where otherwise indicated, where PGE 1 was omitted. The pellet was resuspended to a density of 4x10 8 platelets/ml in a modified Tyrodes-HEPES buffer (145 mM NaCl, 2.9 mM KCl, 10 mM and Lipofectamine before addition to cells in monolayer and left overnight. After 24 hrs, medium was replaced with normal complete medium; after an additional day, the medium was supplemented with 400 µg/ml geneticin. Surviving colonies were expanded and cell lines expressing HA-tagged P2Y 1 receptor isolated by immunofluorescent microscopy as previously described ( 28 data not shown). Receptor expression was assessed using a primary anti-HA-monoclonal antibody (HA-11) and a goat anti-mouse fluorescein-conjugated secondary antibody.
Measurement of cytosolic calcium
Measurement of cytosolic calcium was performed as previously described 29 . Briefly, 3 µM Fura-2-AM was added to platelet rich plasma, and incubated at 30 °C for 45 min in the °C for 60 mins. Cells were washed, removed by trypsinisation and resuspended in PBS in the presence of 0.02u/ml apyrase. Cells were stimulated in suspension at room temperature.
Fluorescence excitation was made at 340 nm and 380 nm and emission at 510 nm was measured using a Hitachi F-4500 spectrofluorimeter. Data are presented as the excitation fluorescence ratio (340:380 nm).
Electrophoresis of proteins and western blotting
Following stimulation, platelets were lysed directly into an equal volume of 2X Laemmli sample solvent and boiled for 5 min . Proteins were resolved by electrophoresis in 10% gradient SDS-PAGE gels. Samples were then transferred to PVDF membranes, using a BioRad Trans-Blot SD semi-dry transfer cell, blocked with 10% bovine serum albumin and incubated for 1 hour at room temperature with appropriate primary antibody (1 µg/ml).
Membranes were then washed before incubation with appropriate secondary antibody followed by thorough washing. Bound peroxidase activity was detected using enhanced chemiluminescence (ECL, Pharmacia-Amersham, UK).
Src in vitro kinase assay
Src activity was assayed on kinase immunoprecipitated from basal or activated platelets.
Reactions were stopped, after 3 min stimulation with agonist, by lysis of platelets with an equal volume of 2X NP-40 extraction buffer (2% Nonidet P40, 300 mM NaCl, 20 mM Tris, 1 were applied to 3x3 cm squares of P81 ion exchange chromatography paper, extensively washed in 0.5% phosphoric acid followed by a wash in acetone. Papers were then dried and labeled Raytide quantified by liquid scintillation counting.
Whole cell cyclic AMP accumulation
Platelets suspensions at 37°C, prepared as described above, were pre-treated for 5 min with a mixture of the phosphodiesterase inhibitor IBMX (1 mM) ± forskolin (1 µM) in the absence or presence of ADP (10 µM). Cyclic AMP accumulation was terminated by addition of ice cold 100 % trichloroacetic acid (TCA) and samples were left to lyse on ice for 1-2 hrs. The resulting samples were spun at 4000g for 5 min and the cAMP-containing supernatant neutralized with 1 M NaOH and TE buffer (50mM Tris-HCl, 4 mM EDTA, pH 7.4). Cyclic AMP levels were subsequently determined in each sample using a binding assay as previously described 30 .
For
RESULTS
P2Y 12 contributes to the ADP-induced calcium response
It is well established that the P2Y 1 receptor expressed on human platelets couples to Gαq and is required for the calcium response to ADP 2, 7 . It is also becoming established that there is a significant degree of cross-talk and interplay between G protein-coupled receptors and their signalling pathways, and we were therefore interested to investigate the possibility that P2Y 12 may play a role in contributing to the ADP-induced calcium response. . In order to demonstrate that these two antagonists had no effect upon P2Y 1 receptors, 1321N1 astrocytoma cells, which express no endogenous P2 receptors [31] [32] [33] [34] , were stably transfected with P2Y 1 . Calcium responses in these cells were monitored in response to ADP, and there was no change in the peak response in the presence of either P2Y 12 antagonist ( Fig. 1(iii) ).
In order to determine the maximal extent of inhibition of the calcium response by the P2Y 12 blocker AR-C69931MX, a concentration-inhibition curve was determined. Increasing concentrations of the antagonist inhibited the ADP-induced calcium rise, which was maximally inhibited by 1 µM, although suppression of the calcium response was not complete, being reduced to between 40 and 50% of the maximal value ( Fig. 2(i) ). This demonstrated that P2Y 12 partially contributed to the calcium response elicited by ADP. This contribution was also demonstrated to be a potentiation of the maximal response to ADP, rather than a synergistic parallel shift in the dose-response curve, since Fig. 2 (ii) shows a drop in the maximal effect of ADP in the presence of AR-C69931MX (1 µM), with no significant change in EC 50 to ADP (2.5±1.0x 10 -7 in the absence of AR-C69931MX compared to 6.1±2.0
x 10 -7 in the presence of AR-C69931MX).
Sub-maximally effective A3P5P reveals a calcium response dependent upon P2Y 12
Figure 3 shows a concentration-response relationship for the P2Y 1 -specific antagonist A3P5P.
At a sub-maximal concentration of A3P5P (200 µM), where the calcium response to ADP was reduced to approximately 25% of the control response, addition of AR-C69931MX (1 µM) was able to abolish completely the calcium response. Thus, at 200 µM A3P5P, the calcium response is dependent upon potentiation by P2Y 12 and this sub-maximal concentration of A3P5P therefore provides a convenient means of studying the P2Y 12 -mediated contribution to the calcium response to ADP.
P2Y 12 contributes to the calcium response to ADP through 2 mechanisms: activation of PI3-kinase and reduction in cellular cAMP
Previous reports have shown that P2Y 12 couples to PI3-kinase (PI3K) and that this is important for ADP-dependent platelet aggregation 23, 24 . We have shown that both ADP and thrombin are able to induce phosphorylation of the kinase PKB on T308 using a phosphopeptide specific antibody and that the PI3K antagonist LY294002 was able to completely abolish phosphorylation of PKB induced by ADP (Fig. 4(i) ). Threonine 308 is phosphorylated by the PI3K-dependent enzyme PDK1, demonstrating that both agonists were able to induce PI3K activation in agreement with previous reports 23, 24 . The mechanism by which the P2Y 12 -mediated activation of PI3K contributes to other ADP-mediated responses has not been clearly elucidated. Using the sub-maximal A3P5P approach described above, we studied the P2Y 12 -dependent calcium response and noted that it was partially inhibited by LY294002, a PI3K-specific antagonist (Fig. 4 (ii) & (iii)). The calcium rise induced by ADP when LY294002 was added in conjunction with maximal AR-C69931MX however was no different than with AR-C69931MX alone (Fig. 4(iii) ). These findings indicate that PI3K plays no role in mediating the P2Y 1 -induced calcium response, but provides a significant component of the P2Y 12 -mediated contribution to the ADP-induced calcium rise.
We were interested to investigate the nature of the remaining component of the P2Y 12 -dependent calcium response, as the response was only partially attenuated by inhibition of PI3K. In the presence of a maximal concentration of AR-C69931MX, where activation of P2Y 12 is fully blocked, ADP is not able to induce a reduction in cAMP. Fig. 4 (iv) shows that in the presence of this inhibitor, the calcium response to ADP is inhibited by approximately 50% and that whilst the adenylate cyclase inhibitor SQ22536 added in addition to AR-C69931MX is able to partially restore the calcium response, it is unable to completely recover the response from inhibition of P2Y 12 . This demonstrates that the P2Y 12 dependent calcium response involves inhibition of cAMP as well as an additional mechanism, which we show is mediated by PI3K.
P2Y 12 contribution to the calcium response is potentiated by the Src kinase inhibitor PP1
G protein-coupled receptors have been shown to couple to activation of tyrosine kinases [35] [36] [37] , and indeed the ADP-induced aggregation response has been shown to partially depend upon Src kinase activity 38 . It was therefore important to address whether Src kinases played a role in the ADP-induced calcium response. Figure 5 (i) shows that inhibition of Src by the selective inhibitor PP1 has no effect upon the calcium to response to ADP alone. In the presence of sub-maximal A3P5P however, where the response depends upon activation of For Figure 5 (ii) shows that PP1 has no effect upon a P2Y 1 -mediated calcium signal (i.e. in the presence of a maximal concentration of AR-C69931MX), and the effect is dependent upon PI3K activity as it is not observable in the presence of LY294002. These data suggest that Src kinases specifically inhibit the PI3K-mediated P2Y 12 -dependent signalling events, but not P2Y 1 -mediated signalling.
Src kinase does not regulate P2Y 12 -mediated inhibition of adenylate cyclase
In order to further clarify the inhibition of P2Y 12 by Src Kinase we decided to study a P2Y 12 -specific signalling event -inhibition of adenylate cyclase. Figure 6 shows that as expected, the P2Y 1 -specific antagonist A3P5P had no effect on ADP-mediated inhibition of a forskolinstimulated rise in cAMP, confirming the lack of role for P2Y 1 in this event. We further showed the absence of a role for Src in this signalling pathway using PP1 and PP3, neither having any effect either alone or in conjunction with each of the receptor antagonists.
P2Y 1 but not P2Y 12 couples to activation of Src kinase
Although we showed that inhibition of Src kinases resulted in the selective potentiation of the PI3K component of the P2Y 12 -dependent contribution to the calcium response, it was important to demonstrate that Src is directly activated by ADP and to determine the receptor to which it is coupled. We chose to assess activation of Src in two ways: (i) identification of phosphorylation of Y416, which correlates with activity and (ii) direct assay of Src activity in vitro. Figure 7 (i) shows that Src is activated directly by ADP, as phosphorylation of Y416 is unaffected by pre-treatment of platelets with either EGTA (1 mM) to block α IIb β 3 or indomethacin (10 µM) to block thromboxane A 2 generation, or both in combination where dense granule secretion is prevented [39] [40] [41] . Collagen is used as a positive control in this assay, and shows that the level of ADP-induced activation is equivalent to that induced by collagen.
By in vitro kinase assay we were able to show that activation of Src lies selectively downstream of P2Y 1 , as it is prevented by pretreatment of platelets with the P2Y 1 -selective antagonist A3P5P but not by the P2Y 12 antagonist, AR-C69931MX (Fig. 7(ii) ). Although the activity of Src stimulated by ADP in the presence of both P2Y 1 and P2Y 12 blockade (51.4 ± 5%) is slightly above basal (43.4 ± 5%), the difference is non-significant (Students t-test, p>0.05).
DISCUSSION
Here we present evidence for cross-talk between the two platelet ADP receptors where P2Y 12 receptor activation positively modulates the P2Y 1 -dependent calcium response, whilst P2Y 1 negatively modulates P2Y 12 through Src kinase activation. We show that modulation of P2Y 1 by P2Y 12 is mediated by both PI3K and inhibition of adenylate cyclase. In turn a negative feedback pathway from P2Y 1 , mediated by Src tyrosine kinase, inhibits the PI3K-dependent signalling component. These findings are summarised in Fig. 7(iii) . Calcium signalling therefore represents a point of cross-talk between these two ADP receptors, and a means of subtly modulating the response of platelets to this important agonist.
Although it has been shown that P2Y 12 is able to potentiate the platelet aggregation response to activation of a variety of platelet receptors, including the Gα q -coupled P2Y 1 and PAR-1, and the collagen receptor GP VI [16] [17] [18] [19] , the signalling mechanisms underlying this potentiation are not clearly elucidated and it is also not clear whether P2Y 12 is able to potentiate platelet responses such as cytosolic calcium rise. In Fig. 1 we have shown that whereas the calcium response to ADP is absolutely dependent upon activation of P2Y 1 , there is also a component that depends upon P2Y 12 . This effect is achieved by a reduction in the maximum calcium response (see Fig. 2 (ii)), suggesting that P2Y 12 is able to potentiate the P2Y 1 -mediated calcium response. We developed an experimental protocol in Fig. 3 27 deliberately used PGE 1 in order to assess the role of cAMP in the inhibition of the calcium response, and were therefore able to reveal a G i -mediated potentiation of the calcium response by P2Y 12 . We too have prepared platelets in the presence of PGE 1 and it was therefore likely that blockade of the calcium response by AR-C69931MX may be partially due to inhibition of the P2Y 12 -mediated Gα i response on adenylate cyclase. We sought to confirm this using the adenylate cyclase inhibitor SQ22536. In Fig. 4 we show that SQ22536
could partially rescue inhibition of the calcium rise by AR-C69931MX, and conclude that part of the P2Y 12 -dependent calcium response is therefore mediated by modulation of platelet cAMP levels. The inhibition of adenylate cyclase is physiologically relevant because platelets are normally continuously exposed to endothelially-derived prostacyclin, and therefore in vivo calcium levels are likely to be modulated by P2Y 12 inhibition of adenylate cyclase. There is substantial evidence demonstrating an inhibitory role for cAMP, through This indicated that Src kinases may negatively regulate P2Y 12 signalling, and it was therefore important to address two questions: (i) which component of P2Y 12 signalling was negatively regulated by Src? and (ii) which receptor (P2Y 1 or P2Y 12 ) couples to activation of Src?
We addressed the first question in two ways. In the first instance, Fig. 6 demonstrates that Src does not regulate the inhibition of adenylate cyclase mediated by P2Y 12 , as PP1 has no effect upon this response. On the other hand, in Fig. 5 (ii) we hypothesised that if the PI3K
For personal use only. on . by guest www.bloodjournal.org From component of the P2Y 12 calcium response was potentiated by PP1, then this potentiation should be abolished in the presence of the PI3K inhibitor LY294002. This was indeed the case, where potentiation of the signal induced PP1 was ablated in the presence of LY294002, indicating that Src kinases may negatively regulate the PI3K component of the signal from P2Y 12 . We had shown in Fig. 4 (i) that ADP induces a weak phosphorylation of PKB on T308, confirming activation of PI3 kinase. We were not however able to demonstrate reliably whether PP1 could potentiate this response, due to the weak nature of the response to ADP.
We cannot therefore conclude whether Src may directly affect PI3 kinase activity. The precise nature of the step regulated by Src kinases is therefore not clear, but taking the evidence from Figs 5 and 6 together, it is likely not to directly regulate the P2Y 12 receptor, but may target a step on the pathway from G βγ , through PI3K to modulation of calcium release or entry. The nature of this modulation step is currently the focus of ongoing investigation in our laboratory.
The second of these questions was addressed by two approaches to assay Src activation state:
(i) western blot analysis of phosphorylation of Y416, which lies in the activation loop of Src, and (ii) a direct in vitro approach to assay activity. Using the first approach we demonstrated that ADP was able to directly activate Src, with no requirement for α IIb β 3 activation or thromboxane A 2 , or secreted mediators. It was important however to use a more direct and quantifiable assay of Src activity to assess the role of P2Y 1 or P2Y 12 in activating Src. For these reasons we chose to assay Src activity directly in vitro using standard approaches, as we have used for other platelet tyrosine kinases 29, 52 . Fig. 7 (ii) shows that the P2Y 12 receptor antagonist AR-C69931MX has no effect upon Src activation by ADP, whereas P2Y 1 blockade by A3P5P reduces Src activity substantially. We conclude therefore that ADP activates Src Reactions were stopped by addition of an equal volume of Laemmli sample solvent, and proteins separated by SDS-PAGE and blotted using the phospho-peptide specific anti-pT308 
